R 0005/13 (Fundamental violation of Article 113 EPC) of 10.02.2014
- European Case Law Identifier
- ECLI:EP:BA:2014:R000513.20140210
- Date of decision
- 10 February 2014
- Case number
- R 0005/13
- Petition for review of
- T 1760/11 2012-11-16
- Application number
- 00108480.5
- IPC class
- C07D 401/12A61P 1/04A61K 31/44
- Language of proceedings
- English
- Distribution
- Distributed to board chairmen and members (B)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Magnesium salt of the (-)-enantiomer of omeprazole and its use
- Applicant name
- AstraZeneca AB
- Opponent name
- Hexal AG
Teva Pharmaceutical Industries Ltd.
Mepha AG
STADA Arzneimittel AG
Pinewood Laboratories Limited
ETHYPHARM
Actavis Group hf.
Lupin Limited
Zentiva a.s.
Generics [UK] Limited
Ratiopharm GmbH
1A Pharma GmbH / Hexal Pharma GmbH
Hörnchen, Ulrich, Dr. - Board
- -
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 112(1)(a)European Patent Convention Art 112a(2)European Patent Convention Art 112a(2)(c)European Patent Convention Art 112a(4)European Patent Convention Art 113(1)European Patent Convention Art 56European Patent Convention R 106European Patent Convention R 107European Patent Convention R 109(2)(a)
- Keywords
- Fundamental violation of the right to be heard (no)
Clearly inadmissible
Clearly unallowable
List of grounds exhaustive
Obligation to raise objection
Sufficiently reasoned (yes) - Catchword
- -
ORDER
For these reasons it is decided that:
"To the extent that the petition for review is not rejected as clearly inadmissible, it is rejected as clearly unallowable."